Advertisement
Singapore markets close in 1 hour 31 minutes

  • Straits Times Index

    3,297.89
    +25.17 (+0.77%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,177.16
    +348.23 (+2.07%)
     

  • FTSE 100

    8,067.67
    +22.86 (+0.28%)
     

  • Bitcoin USD

    66,872.16
    +495.48 (+0.75%)
     

  • CMC Crypto 200

    1,418.33
    -5.77 (-0.41%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Gold

    2,335.80
    -6.30 (-0.27%)
     

  • Crude Oil

    83.40
    +0.04 (+0.05%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • FTSE Bursa Malaysia

    1,570.70
    +9.06 (+0.58%)
     

  • Jakarta Composite Index

    7,149.97
    +39.16 (+0.55%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Why 23andMe Rocketed 27.9% Higher in October

Brett Schafer, The Motley Fool
·2-min read
Why 23andMe Rocketed 27.9% Higher in October

Shares of 23andMe (NASDAQ: ME) jumped 27.9% in October, according to data from S&P Global Market Intelligence. The consumer genetics and pharmaceutical research company announced an acquisition of the telehealth platform Lemonaid Health for $400 million last month, which is the main news that drove up the stock price. 23andMe is the company behind the popular genetic testing kits where consumers can learn about their ancestry background and genetic health.

Continue reading